U.S., April 3 -- ClinicalTrials.gov registry received information related to the study (NCT06906562) titled 'A Phase II Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreas Cancer With FGFR Genetic Alterations' on March 26.
Brief Summary: This study is designed to evaluate the efficacy of the targeted, selective panFGFR inhibitor Pemigatinib when administered as a single agent to patients with genetically selected advanced or metastatic pancreas cancer through assessment of the overall response rate. Additionally, this study will support the molecular characterization of this subset of pancreas cancer through correlative studies
Study Start Date: May 01
Study Type: INTERVENTIONAL
Condition:
Pancreas ...